

# UCSF

## UC San Francisco Previously Published Works

### Title

Incidence of cervical precancers among HIV-seropositive women.

### Permalink

<https://escholarship.org/uc/item/3k24p2f2>

### Journal

American journal of obstetrics and gynecology, 212(5)

### ISSN

0002-9378

### Authors

Massad, L Stewart  
Xie, Xianhong  
D'Souza, Gypsyamber  
et al.

### Publication Date

2015-05-01

### DOI

10.1016/j.ajog.2014.12.003

Peer reviewed

## GYNECOLOGY

# Incidence of cervical precancers among HIV-seropositive women

L. Stewart Massad, MD; Xianhong Xie, PhD; Gypsyamber D'Souza, PhD; Teresa M. Darragh, MD; Howard Minkoff, MD; Rodney Wright, MD; Christine Colie, MD; Lorraine Sanchez-Keeland, PA-C; Howard D. Strickler, MD

**OBJECTIVE:** The objective of the study was to estimate the impact of human immunodeficiency virus (HIV) infection on the incidence of high-grade cervical intraepithelial neoplasia (CIN).

**STUDY DESIGN:** HIV-seropositive and comparison seronegative women enrolled in a prospective US cohort study were followed up with semiannual Papanicolaou testing, with colposcopy for any abnormality. Histology results were retrieved to identify CIN3+ (CIN3, adenocarcinoma in situ, and cancer) and CIN2+ (CIN2 and CIN3+). Annual detection rates were calculated and risks compared using a Cox analysis. Median follow-up (interquartile range) was 11.0 (5.4–17.2) years for HIV-seronegative and 9.9 (2.5–16.0) for HIV-seropositive women.

**RESULTS:** CIN3+ was diagnosed in 139 HIV-seropositive (5%) and 19 HIV-seronegative women (2%) ( $P < .0001$ ), with CIN2+ in 316 (12%) and 34 (4%) ( $P < .0001$ ). The annual CIN3+ detection rate was 0.6 per 100 person-years in HIV-seropositive women and 0.2 per 100

person-years in seronegative women ( $P < .0001$ ). The CIN3+ detection rate fell after the first 2 years of study, from 0.9 per 100 person-years among HIV-seropositive women to 0.4 per 100 person-years during subsequent follow-up ( $P < .0001$ ). CIN2+ incidence among these women fell similarly with time, from 2.5 per 100 person-years during the first 2 years after enrollment to 0.9 per 100 person-years subsequently ( $P < .0001$ ). In Cox analyses controlling for age, the hazard ratio for HIV-seropositive women with CD4 counts less than 200/cmm compared with HIV-seronegative women was 8.1 (95% confidence interval, 4.8–13.8) for CIN3+ and 9.3 (95% confidence interval, 6.3–13.7) for CIN2+ ( $P < .0001$ ).

**CONCLUSION:** Although HIV-seropositive women have more CIN3+ than HIV-seronegative women, CIN3+ is uncommon and becomes even less frequent after the initiation of regular cervical screening.

**Key words:** cervical cancer prevention, cervical intraepithelial neoplasia, human immunodeficiency virus in women

Cite this article as: Massad LS, Xie X, D'Souza G, et al. Incidence of cervical precancers among HIV-seropositive women. *Am J Obstet Gynecol* 2015;212:606.e1-8.

From the Department of Obstetrics and Gynecology, Washington University School of Medicine in St. Louis, St. Louis, MO (Dr Massad); Department of Epidemiology and Population Health (Drs Xie and Strickler) and Obstetrics and Gynecology (Dr Wright), Albert Einstein College of Medicine, and Department of Obstetrics and Gynecology, Montefiore Medical Center (Dr Wright), Bronx, and Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn (Dr Minkoff), NY; Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (Dr D'Souza); Departments of Pathology and Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco School of Medicine, San Francisco (Dr Darragh), and Department of Medicine, University of Southern California School of Medicine, Los Angeles (Ms Sanchez-Keeland), CA; and Department of Obstetrics and Gynecology, Georgetown University School of Medicine, Washington, DC (Dr Colie).

Received Sept. 18, 2014; revised Nov. 12, 2014; accepted Dec. 2, 2014.

The views expressed herein are those of the authors and do not necessarily represent the official views of the National Institutes of Health.

The Women's Interagency HIV Study is supported by the National Institute of Allergy and Infectious Diseases (grants UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (grant UO1-HD-32632). The study is cosupported by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Support is also provided by the National Center for Research Resources (UCSF-CTSI grant UL1 RR024131). Clinical data and specimens in this manuscript were collected by the Women's Interagency HIV Study Collaborative Study Group with centers (principal investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); and Data Coordinating Center (Stephen Gange). Additional support, including for statistical analysis, was provided by grant R01 CA85178 (H.D.S.).

T.M.D. received research supplies for anal cytology, honorarium for webinar on anal cancer screening (2012) from Hologic; stock options from the OncoHealth Advisory Board (ongoing); honorarium paid to UCSF from Roche (2013). A study of H.D.S. involves free blinded testing using HPV E6/E7 protein assays by Arbor Vita (Fremont, CA), p16/Ki67 cytology by MTM Laboratories/Ventura—Roche (Mannheim, Germany), MCM-2/TOP2A cytology from BD Diagnostics (Franklin Lakes, NJ). No financial payments to H.D.S. or his home institution were received. The other authors report no conflict of interest.

Corresponding author: L. Stewart Massad, MD. [massadl@wudosis.wustl.edu](mailto:massadl@wudosis.wustl.edu)

0002-9378/\$36.00 • © 2015 Elsevier Inc. All rights reserved. • <http://dx.doi.org/10.1016/j.ajog.2014.12.003>

Compared with human immunodeficiency virus (HIV)-seronegative women, HIV-seropositive women face a higher risk for coinfection by human papillomaviruses (HPV) and abnormal Papanicolaou tests.<sup>1-3</sup> Despite this fact, cancer incidence in HIV-seropositive women receiving cervical cancer prevention measures was not significantly increased.<sup>4,5</sup>

The reasons underlying this discrepancy are unclear. Highly oncogenic HPV types, such as 16, are minimally increased in HIV.<sup>6</sup> Women in a cancer prevention program may have a high frequency of precancers that are identified and eliminated, blocking oncogenesis. However, cervical treatments for HPV-related disease were not common among women in 2 US HIV cohorts.<sup>7</sup> Alternatively, HPV infections may progress rapidly to precancer and then cancer more rapidly in HIV-seropositive than seronegative women, yet the disparity may become apparent only after years of observation. Even when assessed across time, most abnormal Papanicolaou tests in HIV-seropositive women are atypical or low grade, not the high-grade results strongly correlated with precancer.<sup>3</sup> Cervical precancers may be similarly infrequent or may not progress over the short observation periods of most prior studies.

The objective of this study was to describe the incidence across time of cervical precancer among HIV-seropositive and comparison of HIV-seronegative US women in a cancer prevention program.

## MATERIALS AND METHODS

The Women's Interagency HIV Study (WIHS) is a US multicenter cohort study of health outcomes among HIV-seropositive women. The study also has followed up at-risk HIV-seronegative comparison women who were frequency matched for risk factors, including age, race/ethnicity, level of education, injection drug use since 1978, and total number of sexual partners since 1980. Enrollment began on Oct. 3, 1994, at 6 study consortia and over time enrolled 4068 women, including those enrolled during expansions from 2001-2002 and 2011-2012, and was designed to ensure

that the cohort reflected the evolving HIV epidemic in US women.<sup>8,9</sup>

At each site, human subjects committees reviewed and approved the study, and all participants gave written informed consent. Follow-up continues, but this analysis includes information on histological outcomes through Sept. 30, 2013.

According to study-wide protocol, single-slide conventional Papanicolaou smears were obtained every 6 months using spatula and brush for HIV-seropositive and HIV-seronegative women. Colposcopy was required by study protocol for any epithelial cytological abnormality, including atypical squamous cells of uncertain significance.

HPV testing was performed for research only and was not used in clinical management, including for atypical squamous cells of uncertain significance triage. Biopsy results were interpreted at local sites and were not centrally reviewed. Abnormal results were categorized as cervical intraepithelial neoplasia (CIN) grades 1, 2, or 3; adenocarcinoma in situ; or cancer. Unspecified high-grade dysplasia was classified with CIN3. We examined CIN3 or worse (CIN3+) and CIN2 and worse (CIN2+) in separate analyses. Cervical disease treatments were identified by self-report, supplemented by medical record abstraction when available.

To minimize confusing prevalent with incident disease, women diagnosed with CIN3+ and CIN2+ within 6 months of study enrollment were excluded. Women who had hysterectomies at baseline were excluded, and women were censored at hysterectomy during follow-up. Those without follow-up were also excluded.

Contingency tables were generated to assess baseline patient characteristics by HIV serostatus. Pearson's  $\chi^2$  tests were used to compare baseline characteristics between HIV-seropositive and HIV-seronegative women. Wilcoxon rank-sum tests were used to compare medians. The Kaplan-Meier method was used to calculate the cumulative incidence. The incidence rates between HIV-seropositive and HIV-seronegative women were compared using Cox models with the normal approximation

to the binomial distribution. And the incidence rates before 2 years and those after 2 years were compared using the bootstrapping method. All statistical tests defined significance as  $P < .05$  using 2-sided tests.

## RESULTS

Table 1 presents the demographic characteristics at enrollment for the 3465 women at risk for CIN3+ during follow-up (900 HIV seronegative, 2565 HIV seropositive). The median age (interquartile range) for the HIV-seropositive women was 35 (30-41) years and for HIV-seronegative women was 33 (26-40) years ( $P < .0001$ ). The HIV-seropositive women were less likely to be smokers at enrollment and were more likely to have been abstinent during the 6 months before enrollment. Although the distribution of the reported lifetime number of male partners was different, with more HIV-seropositive women reporting the extremes of partner number, the median number of partners was 10 for both HIV-seropositive and HIV-seronegative women.

HIV-related disease characteristics among seropositive women are summarized in Table 1. Most HIV-seropositive women had CD4 cell counts greater than 200/cmm, with HIV RNA levels below or just above the threshold for detection at study initiation, which for most women was less than 4,000 copies/cmm. Most had never been diagnosed with acquired immunodeficiency syndrome.

Median follow-up (interquartile range) was 11.0 (5.4-17.2) years for HIV-seronegative and 9.9 (2.5-16.0) for HIV-seropositive women. Follow-up rates for HIV-seropositive and HIV-seronegative women at 3 years were 86% and 80%, 82% and 74% at 5 years, and 71% and 62% at 10 years. Only 19 HIV-seronegative women (2%) were diagnosed with CIN3+, whereas CIN3+ was found in 139 HIV-seropositive women (5%) ( $P < .0001$ ).

The risk of CIN2+ was substantially greater, occurring in 34 HIV-seronegative women (4%) and 316 HIV-seropositive women (12%) ( $P < .0001$ ). The annual

TABLE 1

**Enrollment characteristics of HIV-seropositive (HIV+) and seronegative (HIV-) women**

Characteristic	Overall (n = 3465)	HIV- (n = 900)	HIV+ (n = 2565)	P value HIV+ vs HIV-
Race, n (%)				.75
White	489 (14)	119 (13)	370 (14)	
Hispanic	897 (26)	236 (26)	661 (26)	
Black	1957 (56)	510 (57)	1447 (56)	
Other	122 (4)	35 (4)	87 (3)	
Smoking status, n (%)				.01
Never smoked	1158 (34)	278 (31)	880 (34)	
Former smoker	514 (15)	119 (13)	395 (15)	
Current smoker	1778 (52)	500 (56)	1278 (50)	
Education, n (%)				.14
Less than high school	1288 (37)	310 (35)	978 (38)	
High school	1034 (30)	272 (30)	762 (30)	
Beyond high school	1134 (33)	312 (35)	822 (32)	
Lifetime male sexual partners, n (%)				.001
<5	769 (23)	167 (19)	602 (24)	
5-9	716 (21)	194 (22)	522 (21)	
10-49	1142 (34)	340 (38)	802 (32)	
≥50	779 (23)	189 (21)	590 (23)	
Male sexual partner in past 6 months, n (%)				< .0001
0	865 (26)	152 (17)	713 (2)	
1	1833 (54)	439 (49)	1394 (56)	
2	372 (11)	146 (16)	226 (9)	
≥3	317 (9)	158 (18)	159 (6)	
CD4+ cell count/cmm, n (%)				
>500			889 (36)	
200-500			1099 (44)	
<200			505 (20)	
HIV viral load (copies/cmm), n (%)				
≤4000			1057 (42)	
4001-20,000			518 (21)	
20,001-100,000			532 (21)	
>100,000			403 (16)	
Ever AIDS, n (%)				
No			2037 (79)	
Yes			528 (21)	

AIDS, acquired immunodeficiency syndrome; CIN, cervical intraepithelial neoplasia; HIV, human immunodeficiency virus.

Massad. Cervical precancer incidence in HIV-positive women. *Am J Obstet Gynecol* 2015.

detection rate of CIN3+ was 0.6 per 100 person-years in HIV-seropositive women and 0.2 per 100 person-years in HIV-seronegative women ( $P < .0001$ ). Similar rates for CIN2+ were 1.4 and 0.4 per 100 person-years ( $P < .0001$ ).

The annual detection rate of CIN3+ and CIN2+ fell over time (Figure). We estimated the detection rate of these endpoints before and after the first 2 years after enrollment, excluding presumed prevalent disease discovered during the first 6 months of study. The annual rate of CIN3+ detection among HIV-seropositive women was 0.9 per 100 person-years during the first 2 years of study and 0.4 per 100 person-years during subsequent follow-up ( $P < .0001$ ). CIN2+ incidence among these women fell similarly with time, from 2.5 per 100 person-years during the first 2 years after enrollment to 0.9 per 100 person-years subsequently ( $P < .001$ ).

The incidence was lower among HIV-seronegative women but also fell with time: CIN3+ incidence dropped from 0.4 per 100 person-years during the first 2 years to 0.1/100 person-years thereafter ( $P = .02$ ), whereas CIN2+ incidence decreased from 0.7 per 100 person-years early in the study to 0.2 per 100 person-years afterward ( $P = .03$ ). The incidence of CIN3+ and CIN2+ was higher among HIV-seropositive than HIV-seronegative women at both time points ( $P < .0001$ ), except that the difference in CIN3+ during the first years was not significant ( $P = .07$ ). The decline in risk after 2 years persisted among HIV-seropositive women after controlling for CD4 count women and for age (hazard risk, 0.18 after 2 years; 95% confidence interval [CI], 0.08–0.40;  $P < .0001$ ). There were insufficient data to conduct a similar multivariate analysis among HIV-seronegative women.

If the observed increased risk of CIN3+ and CIN2+ in HIV-seropositive women is related to immunosuppression, then risk should rise with more severe immunosuppression. In fact, the incidence of CIN3+ was 0.2 per 100 person-years (95% CI, 0.1–0.3) among HIV-seronegative women, 0.5 (95% CI,

0.3–0.6;  $P = .003$  compared with HIV-seronegative women) among HIV-seropositive women with CD4 counts greater than 500/cmm, 0.5 (95% CI, 0.4–0.7;  $P = .0003$ ) among women with CD4 counts of 200–500/cmm, and 1.0 (95% CI, 0.7–1.3;  $P < .0001$ ) among women with CD4 counts less than 200/cmm.

CIN2+ risk rose similarly, from 0.4 per 100 person-years (95% CI, 0.2–0.5) among HIV-seronegative women to 1.2 (95% CI, 0.9–1.4;  $P < .0001$  compared with HIV-seronegative women) among HIV-seropositive women with CD4 counts greater than 500/cmm, 1.4 (95% CI, 1.1–1.6;  $P < .0001$ ) for women with CD4 counts of 200–500/cmm, and 2.3 (95% CI, 1.7–2.8;  $P < .0001$ ) among women with CD4 counts less than 200/cmm.

Although significant, these results may obscure the impact of CD4 count on CIN3+ and CIN2+ because levels may vary over time. In an analysis adjusting for CD4 count as a time-varying factor, we observed a progressive rise in CIN3+ and CIN2+ risk as CD4 counts fell (Table 2). In Cox analyses controlling for age and the timing of diagnosis, the hazard ratio for HIV-seropositive women with CD4 counts less than 200/cmm compared with HIV-seronegative women was 4.6 (95%


CI, 3.0–7.2) for CIN3+ and 3.5 (95% CI, 2.6–4.7) for CIN2+ ( $P < .0001$  for both).

We further explored factors associated with the incidence of CIN3+ and CIN2+. As shown in Table 3, CD4 count remained strongly associated with both CIN3+ and CIN2+. Smoking was associated with a higher and increasing age with a lower risk. Lifetime number of sexual partners was not associated with either CIN3+ or CIN2+ after controlling for these factors. Recent number of sexual partners was linked to CIN2+ but not CIN3+.

We assessed whether the incidence of CIN3+ and CIN2+ might have been reduced by the treatment of fewer lesions. In all, 1270 women reported cervical disease treatment during follow-up (1040 HIV-seropositive and 230 HIV-seronegative women). However, the incidence of CIN2+ did not appear to decline after treatment.

Among treated women, the annual incidence of CIN3+ before treatment was 0.5 per 100 person-years among HIV-seropositive women, whereas that of HIV-seronegative women was 0.2 per 100 person-years. After treatment, CIN3+ incidence was 0.7 per 100 person-years among HIV-seropositive and 0.3 per 100 person-years among HIV-seronegative women. Although the

**FIGURE**  
Cumulative incidence of CIN3+ and CIN2+



Cumulative incidence of CIN3+ and CIN2+ among HIV-seropositive and HIV-seronegative women. For both, data were  $P < .0001$  by log-rank test.

CIN, cervical intraepithelial neoplasia; HIV, human immunodeficiency virus.

Masad. Cervical precancer incidence in HIV-positive women. *Am J Obstet Gynecol* 2015.

**TABLE 2**  
**Association of CD4 count with incidence of CIN3+ and CIN2+**

Variable	Hazard ratio	95% LCL	95% UCL	P value
<b>CIN3+</b>				
Timing of diagnosis				
Initial 2 y (referent)	1.0			
After 2 y	0.18	0.08	0.40	< .0001
CD4+ T-cell count				
>500 (referent)	1.0			
200-500	1.40	0.88	2.21	.16
<200	4.62	2.95	7.22	< .0001
Age, y				
<30 (referent)	1.0			
30-34	0.87	0.46	1.65	.66
35-39	0.94	0.51	1.71	.84
40-44	0.66	0.34	1.26	.21
≥45	0.73	0.38	1.39	.33
<b>CIN2+</b>				
Timing of diagnosis				
Initial 2 y (referent)	1.0			
After 2 y	0.30	0.17	0.51	< .0001
CD4+ T-cell count/cmm				
>500 (referent)	1.0			
200-500	1.52	1.14	2.03	.004
<200	3.45	2.56	4.65	< .0001
Age, y				
<30 (referent)	1.0			
30-34	0.60	0.41	0.87	.01
35-39	0.69	0.49	0.98	.04
40-44	0.39	0.26	0.59	< .0001
≥45	0.46	0.31	0.69	.0001

Controlled for age and time of diagnosis.

CIN, cervical intraepithelial neoplasia; LCL, lower confidence limit; UCL, upper confidence limit.

Massad. Cervical precancer incidence in HIV-positive women. *Am J Obstet Gynecol* 2015.

rate of CIN3+ among HIV-seropositive women was higher than among HIV-seronegative women before and after self-reported treatment, the difference reached statistical significance only during the pretreatment interval ( $P = .01$ ), not during the posttreatment interval ( $P = .15$ ). The HIV-seropositive women who were treated for cervical disease also had higher rates of CIN2+ before and after treatment: 1.6 vs 0.4 per 100

person-years among HIV-seronegative women before treatment ( $P < .0001$ ) and 1.7 vs 0.4 per 100 person-years after treatment ( $P = .0002$ ).

#### COMMENT

HIV-seropositive women have a higher risk for CIN3+ than HIV-seronegative women, but their absolute risk is low across years of observation, well less than 1% annually and 5% across a median

of 10 years of observation. Women with HIV warrant careful cervical cancer screening and meticulous investigation after abnormal screening results, with treatment for histologically confirmed precancers. However, HIV-seropositive women with equivocal abnormalities should not be subjected to treatment solely because they are perceived to be at high risk. Risk rises with increasing immunosuppression as measured by CD4 count, and more aggressive intervention may be appropriate for more severely immunosuppressed women, provided expected survival in the face of HIV disease remains substantial.

CIN2+ is more common than CIN3+ in HIV-seropositive women, occurring in about 1% annually and 12% during a 10-year follow-up. This risk is also higher than in HIV-seronegative women. The oncogenic potential of CIN2 is uncertain because it appears to include some lesions with substantial and others with little malignant potential.<sup>10</sup> Nevertheless, treatment of CIN2 may have aborted the development of CIN3+ in some women.

Cervical disease treatments in WIHS were done off study, although sometimes in the same clinical sites. Some were tracked by participant self-report, which may undercount treatments. Cervical cancer incidence in HIV-seropositive women in our cervical cancer prevention program remains low across a decade of observation.<sup>5</sup> The low absolute risk of CIN3+ across a similar time span suggests that women with HIV receiving care that includes cervical cancer prevention do not face an impending epidemic of cervical cancer that has yet to manifest itself.

The incidence of CIN3+ fell after the first 2 years of our study, and this was true for HIV-seropositive women, regardless of age and CD4 count. Although we tried to minimize the impact of prevalent disease on incidence estimates by excluding cases diagnosed during the first 6 months after enrollment, cytology is insensitive and non-compliance with colposcopy referral was a problem early in the study. The higher initial detection rate we observed

**TABLE 3**  
**Multivariable analysis of correlates of CIN3+ and CIN2+**

Variable	Hazard Ratio	95% LCL	95% UCL	P value
<b>CIN3+</b>				
CD4+ T-cell count				
HIV negative (referent)	1.0			< .0001 <sup>a</sup>
>500	1.88	1.04	3.40	.04
200-500	2.45	1.40	4.27	.002
<200	7.78	4.51	13.42	< .0001
Age, y				
<30 (referent)	1.0			
30-34	0.66	0.37	1.17	.15
35-39	0.64	0.37	1.10	.11
40-44	0.46	0.25	0.83	.01
≥45	0.53	0.29	0.97	.04
Smoking				
Never smoked (referent)	1.0			
Former smoker	0.85	0.47	1.54	.60
Current smoker	2.08	1.35	3.21	.001
Lifetime male sexual partners, n				
<5 (referent)	1.0			
5-9	1.71	1.03	2.84	.04
10-49	1.11	0.67	1.85	.69
≥50	1.24	0.72	2.13	.43
Male sexual partners in past 6 mo, n				
0 (referent)	1.0			
1	1.20	0.83	1.75	.34
2	0.68	0.30	1.54	.35
≥3	0.62	0.22	1.78	.37
<b>CIN2+</b>				
CD4+ T-cell count				
HIV negative (referent)	1.0			< .0001 <sup>a</sup>
>500	2.86	1.89	4.33	< .0001
200-500	4.23	2.86	6.25	< .0001
<200	9.50	6.36	14.18	< .0001
Age, y				
<30 (referent)	1.0			
30-34	0.53	0.37	0.76	.001
35-39	0.62	0.45	0.86	.004
40-44	0.33	0.22	0.48	< .0001
≥45	0.44	0.30	0.65	< .0001

Massad. Cervical precancer incidence in HIV-positive women. *Am J Obstet Gynecol* 2015.

(continued)

may be attributable in part to the delayed diagnosis of prevalent lesions.

In addition, the treatment of CIN1 accounted for more than a third of all cervical treatments during the initial years of the study,<sup>7</sup> and we cannot exclude the possibility that the removal of lesser precursors may have reduced the subsequent risk for CIN3+ and CIN2+. Alternatively, the initiation of highly active antiretroviral therapy after study enrollment and corresponding engagement in HIV care might have reduced the risk for CIN3+ and CIN2+ by reducing immunosuppression and facilitating immune-mediated clearance of HPV-induced cervical lesions beyond what can be addressed by CD4 count.<sup>11</sup>

Regardless of the cause of the lower incidence of CIN3+ and CIN2+ after 2 years in study, the finding supports the concept that HIV-seropositive women receiving regular gynecological care are at low absolute risk for CIN3+. We have shown that the risk for CIN3+ after serial negative Papanicolaou tests or a single combination Papanicolaou/HPV cotest is low.<sup>12,13</sup> Despite a statistically increased risk of CIN3+, the low absolute risk for CIN3+ among HIV-seropositive women after 2 years in care reinforces the recommendation that after initial negative cervical cancer screening tests, subsequent screening intervals can be safely lengthened.

Neither recent nor lifetime number of sexual partners was associated with CIN3+ after controlling for CD4 count, age, and smoking. This suggests that host factors that determine HPV clearance vs persistence, as well as the subsequent accumulation of somatic epigenetic and genetic changes, may be more important than simple HPV exposure in determining the risk for cervical precancer and cancer among HIV-seropositive women. The recent number of sexual partners was associated with CIN2+ but not CIN3+ after controlling for CD4 count, age, and smoking. This is consistent with the concept that many cases of CIN2 are recently acquired HPV infections of uncertain oncogenic potential.

This study has several strengths, including the prospective nature of the

**TABLE 3**  
**Multivariable analysis of correlates of CIN3+ and CIN2+ (continued)**

Variable	Hazard Ratio	95% LCL	95% UCL	P value
<b>Smoking</b>				
Never smoked (referent)	1.0			
Former smoker	0.96	0.66	1.39	.83
Current smoker	1.87	1.41	2.47	< .0001
<b>Lifetime male sexual partners, n</b>				
<5 (referent)	1.0			
5-9	1.13	0.81	1.57	.49
10-49	1.02	0.74	1.40	.92
≥50	0.98	0.69	1.39	.90
<b>Male sexual partners in past 6 mo, n</b>				
0 (referent)	1.0			
1	1.56	1.19	2.05	.002
2	1.69	1.09	2.60	.02
≥3	1.46	0.84	2.53	.18

CIN, cervical intraepithelial neoplasia; LCL, lower confidence limit; UCL, upper confidence limit.

<sup>a</sup> P for trend.

Massad. Cervical precancer incidence in HIV-positive women. *Am J Obstet Gynecol* 2015.

value of repeated Papanicolaou testing is good,<sup>17</sup> and negative colposcopy after borderline cervical abnormalities is reassuring.<sup>18</sup>

Longer studies, including WIHS as it continues into its third decade of follow-up, should better define the long-term cancer risk in the face of frequent carcinogenic HPV infection and abnormal cytology. ■

#### ACKNOWLEDGMENTS

Contribution to authorship include the following: Dr Massad conceived the analysis, contributed patient data, and wrote the first manuscript draft. Drs D'Souza, Darragh, Minkoff, Assaye, Wright, and Evans and Ms Sanchez-Keeland all contributed to the study execution and manuscript development. Drs Xie and Strickler contributed to the concept development and performed the statistical analyses. All authors have approved the final manuscript for submission to BJOG. Ethics approval was obtained at every site and sub-site and was reapproved repeatedly over the past 20 years of the study. Documentation is not provided because of the large number of approvals required.

#### REFERENCES

1. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. *J Natl Cancer Inst* 1999;91:226-36.
2. Massad LS, Riestler KA, Anastos KM, et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Inter-agency HIV Study Group. *J Acquir Immune Defic Syndr* 1999;21:33-41.
3. Massad LS, Seaberg EC, Wright RL, et al. Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up. *Obstet Gynecol* 2008;111:1388-93.
4. Massad LS, Seaberg EC, Watts DH, et al. Low incidence of invasive cervical cancer among HIV infected US women in a prevention program. *AIDS* 2004;18:109-13.
5. Massad LS, Seaberg EC, Watts DH, et al. Long-term incidence of cervical cancer in women with HIV. *Cancer* 2009;115:524-30.
6. Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. *J Natl Cancer Inst* 2003;95:1062-71.
7. Massad LS, Fazzari MJ, Anastos K, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. *J Low Genit Tract Dis* 2007;11:90-7.

study and the use of CIN3+ as an endpoint, in which most prior studies have been retrospective and have relied on cervical cytology, which can be nonspecific and may overestimate CIN2+.<sup>14</sup>

Our results are limited by several factors. Biopsies were not centrally reviewed, and some misclassification may have occurred. Nevertheless, the low incidence of cervical cancer in our cohort is consistent with a relatively low incidence of cervical precancer and suggests few cases were missed.

Cervical disease treatments were not provided in this observational study and self-reporting may have undercounted treatment. Some women with CIN1 were treated early in the study. Although this might have reduced the progression of lower-grade CIN to CIN3+, our conclusion that new CIN3+ is uncommon in HIV-seropositive women in a cancer prevention program remains valid. Women in WIHS are screened with cytology semiannually, more frequently than under current guidelines, but HIV-seropositive women

with negative screening results are at low risk for CIN3+,<sup>12,13</sup> and similar low incidence should result from standard screening.

Colposcopy compliance among women with HIV can be suboptimal,<sup>15</sup> but serial observation over years should have identified most women with oncogenic lesions. HIV-seropositive women who have not been screened may face higher risk, as reflected by the higher incidence of CIN3+ identified soon after the study launch. We cannot exclude the possibility that CIN3+ incidence may rise after periods longer than we observed women, but WIHS is ongoing.

Despite an increased relative risk of cervical disease compared with HIV-seronegative women, the low absolute incidence of CIN3+ in HIV-seropositive women warrants cautious management of abnormalities detected in cervical cancer prevention programs. Clinicians need not rush to treat minor lesions out of fear of rapid progression. In fact, progression of CIN1 is uncommon,<sup>16</sup> the negative predictive



8. Barkan SE, Melnick SL, Martin-Preston S, et al. The Women's Interagency HIV Study. *Epidemiology* 1998;9:117-25.
9. Bacon M, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. *Clin Diag Lab Immunol* 2005;12:1013.
10. Darragh TM, Colgan TJ, Cox JT, et al; for the LAST Project Work Groups. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. *J Low Genit Tract Dis* 2012;16:205-42.
11. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. *J Infect Dis* 2010;201:681-90.
12. Massad LS, D'Souza G, Tian F, et al. Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus. *Obstet Gynecol* 2012;120:791-7.
13. Keller MJ, Burk RD, Xie X, et al. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. *JAMA* 2012;308:362-9.
14. Massad LS, Schneider M, Watts H, et al. Correlating Papanicolaou smears, colposcopic impression and biopsy. Results from the Women's Interagency HIV Study. *J Lower Genital Tract Dis* 2001;5:212-8.
15. Cejtin HE, Komaroff E, Massad LS, et al. Adherence to colposcopy among women with HIV infection. *J Acquir Immune Defic Syndr* 1999;22:247-52.
16. Massad LS, Evans CT, Minkoff H, et al. Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus. *Obstet Gynecol* 2004;104:1077-85.
17. Massad LS, D'Souza G, Tian F, et al. Negative predictive value of Pap testing: implications for screening intervals for women with human immunodeficiency virus. *Obstet Gynecol* 2012;120:791-7.
18. Massad LS, Evans CT, Strickler HD, et al. Outcome after negative colposcopy among human immunodeficiency virus-infected women with borderline cytologic abnormalities. *Obstet Gynecol* 2005;106:525-32.